Lates News

According to Every AI Express, open source securities published a research report on September 23, giving Tianjin Pharmaceutical (600535.SH) a buy rating. The main reasons for the rating include: 1) outstanding advantages in specific thrombolytic mechanisms and obvious clinical effectiveness; 2) entering the AIS disease market, with the potential for synergistic development of dual indications. (Daily Economic News)